1. Home
  2. NRT vs EQ Comparison

NRT vs EQ Comparison

Compare NRT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

N/A

Current Price

$6.95

Market Cap

81.0M

Sector

Energy

ML Signal

N/A

Logo Equillium Inc.

EQ

Equillium Inc.

N/A

Current Price

$1.39

Market Cap

89.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NRT
EQ
Founded
1975
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
89.4M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
NRT
EQ
Price
$6.95
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $8.56
AVG Volume (30 Days)
20.5K
★ 439.5K
Earning Date
09-08-2026
11-12-2026
Dividend Yield
★ 9.69%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.70
N/A
Revenue
N/A
★ $41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.99
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.52
$1.16
52 Week High
$10.49
$6.20

Technical Indicators

Market Signals
Indicator
NRT
EQ
Relative Strength Index (RSI) 22.01 44.12
Support Level $6.87 $1.30
Resistance Level $8.74 $1.51
Average True Range (ATR) 0.34 0.13
MACD -0.10 0.04
Stochastic Oscillator 15.88 62.86

Price Performance

Historical Comparison
NRT
EQ

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: